Pharmaceutical-grade 1,3-dimethyl-2-imidazolidinone (DMI, CAS 80-73-9) is a high-boiling, water-miscible dipolar aprotic liquid. In the downstream applications described below, it is handled as a processing solvent and co-solvent; it is not a compendial active pharmaceutical ingredient, and no USP, Ph.Eur., or JP monograph exists for the substance. The normal boiling point of approximately 225 °C controls drying, residual solvent removal, and terminal sterilization behavior. Typical release parameters for pharmaceutical-grade DMI are shown in the first table; actual batch release criteria are defined in the supplier quality agreement and confirmed by the downstream drug product manufacturer.

Tablet wet granulation uses DMI when the active substance has an aqueous solubility below 0.1 mg/mL and the binder solution must keep the drug dissolved during high-shear wet massing. In a 10 L top-drive high-shear granulator, a granulating fluid containing 5–15% w/w DMI, 10–25% w/w ethanol, and 60–85% w/w purified water is sprayed at 5–10 g/min per kg of dry powder onto a lactose–microcrystalline cellulose–crospovidone blend. The main impeller is operated at 600–900 rpm during binder addition, then increased to 1,200–1,500 rpm with a chopper at 2,000–3,000 rpm for 2–4 min. The wet mass is discharged and wet-milled through a 2.0 mm screen before drying in a fluid-bed dryer with inlet air at 55–65 °C and dew point not above 10 °C. Drying is stopped at a loss on drying of 1.0–2.0% w/w, but DMI is not easily removed at that endpoint because its boiling point is 225 °C; residual DMI in dried granules must therefore be measured by headspace gas chromatography with flame-ionization detection according to USP <467>. If the residual level exceeds the qualified daily intake, a vacuum oven step at 70–80 °C may be added, but this can alter granule friability and compactability. Granules are then milled through a 0.8 mm Conidur screen and compressed on a rotary tablet press with 8 mm round concave punches at 8–12 kN main compression force. Tablet hardness and ejection force are sensitive to residual DMI because the solvent can plasticize amorphous regions of the binder; compaction runs should therefore bracket the expected residual DMI range. Content uniformity, disintegration, and dissolution are measured under USP <905>, <701>, and <711> respectively. In-process control under 21 CFR 211.110 requires the granulating fluid flow rate and exhaust humidity to be recorded so the DMI-to-water ratio does not drift during the batch.

How Does a Liquid-Filled Hard Capsule Shell React to DMI When Water Is Reduced Below 3%?

In hard capsule liquid-fill development, DMI is evaluated as a non-aqueous co-solvent for crystalline active substances that are poorly soluble in medium-chain triglycerides and propylene glycol monocaprylate. The fill is prepared in a nitrogen-blanketed, jacketed vessel at 35–45 °C with a polytetrafluoroethylene-coated anchor stirrer. DMI is added at 5–20% w/w of the finished fill mass; the balance is a lipophilic diluent such as glyceryl caprylate/caprate or propylene glycol monocaprylate type II, with a water fraction below 3% w/w. Target fill viscosity at 35 °C is 0.3–1.0 Pa·s for dosing on a laboratory-scale capsule filling machine equipped with a positive-displacement pump. Above 20% w/w DMI, gelatin capsule shells can soften during accelerated storage because DMI redistributes water from the shell and depresses the shell glass transition temperature. Shell compatibility is checked by weight gain not more than 2.5% after 24 h at 40 °C and by puncture force not less than 1.2 N on the capsule body at 20 °C. Hypromellose shells usually show lower visual change but can exhibit band separation when the fill contains more than 15% w/w water-free DMI without a lipophilic diluent. Because the fill is not dried after preparation, the DMI dose is calculated from the fill weight: a 200 mg fill with 10% w/w DMI delivers 20 mg DMI per capsule, and that daily exposure is compared with a qualified permitted daily exposure derived under ICH Q3C Section 3.4. The fill intermediate is deaerated below 500 mbar absolute for 15 min before encapsulation to avoid bubbles that interfere with fill weight control. DMI is assayed in the fill by gas chromatography against an internal standard. Dissolution of the encapsulated liquid fill is monitored under USP <711>, and antimicrobial effectiveness is evaluated under USP <51> if the fill contains free water.

Extrusion-spheronization for minitablet or multiparticulate granules uses DMI as part of the wet-massing liquid when the formulation must remain extrudable at lower water content. A powder blend of microcrystalline cellulose, lactose monohydrate, and the active substance is dry-mixed in a low-shear tumble blender for 10 min. The granulating liquid contains 5–10% w/w DMI in purified water and is added to a final liquid-to-solids ratio of 30–45% w/w, depending on the microcrystalline cellulose grade. The wet mass is extruded through a dome extruder fitted with a 0.8 mm screen at 20–50 rpm; screen pressure is kept below 40 bar to avoid premature densification. Extrudate is spheronized on a cross-hatch friction plate at 600–1,200 rpm for 3–6 min. DMI reduces the amount of water required to reach the plastic mass endpoint because it is water-miscible and lowers the surface tension of the granulating liquid; it is not a binder and does not replace polyvinylpyrrolidone or hydroxypropylcellulose when a true dry binder is required. Granule drying after spheronization is performed in a fluid-bed dryer at 55–65 °C to a moisture specification of 0.5–2.0% w/w. The DMI residue in the final multiparticulates must be controlled by the same ICH Q3C logic applied to tablet granules, though the residual level can differ because pellet surface area per unit mass is larger for 0.8–1.0 mm pellets. Particle-size distribution after spheronization is measured by sieve analysis; the target fraction between 0.7 and 1.0 mm is normally not less than 85% w/w. Fines below 0.3 mm are removed because they can cause content uniformity failure when multiparticulates are filled into hard capsules or compressed into minitablets. Bulk density, tapped density, and flow are controlled under USP <616> when the product is filled volumetrically into sachets or capsules.

When Parenteral Administration Requires a Water-Miscible Non-Aqueous Co-Solvent

For injectable products, DMI is introduced only when the active substance cannot be solubilized by pH adjustment or by buffered aqueous media alone. The development batch is prepared in a Grade C cleanroom with Grade A filling. DMI is introduced at 5–20% v/v into a buffered aqueous vehicle, typically with a phosphate or citrate buffer, and the pH is adjusted to 4.0–7.5 with sodium hydroxide or hydrochloric acid. The tonicity agent is added to reach an osmolality of 280–320 mOsm/kg, measured by freezing-point depression under USP <785>. The solution is filtered through a 0.22 µm polyvinylidene difluoride membrane before filling into Type I borosilicate glass vials. Sub-visible particulate matter is measured by light obscuration under USP <788> with limits of not more than 6,000 particles per container ≥10 µm and 600 particles per container ≥25 µm for small-volume injections. Visible particulates are inspected under USP <790>. Because DMI can alter the aqueous dissolution of borosilicate glass surfaces during terminal sterilization, glass delamination screening under USP <1660> is performed on vials filled with the DMI-containing vehicle and autoclaved at 121 °C for 15 min. The high boiling point of DMI prevents evaporative loss during terminal sterilization, but it also means that DMI is not removed by lyophilization unless an extended primary drying step is designed. Endotoxin is controlled to not more than 0.5 EU/mL for intravenous administration. Published DMI-specific parenteral safety data are limited; therefore a daily DMI exposure limit is justified from repeat-dose toxicology studies and included in the eCTD Module 3 rather than by reference to a compendial monograph. Hemolysis screening is performed in diluted human whole blood; if hemolysis exceeds 1% at the intended administration concentration, the DMI fraction is reduced. Formulations intended for subcutaneous or intramuscular injection require local tolerance testing because DMI can extract plasticizers from elastomeric vial closures and syringe plungers; compatibility with chlorobutyl closures is screened by seal integrity and extractables under USP <381>. If the injectable is multidose, antimicrobial effectiveness testing under USP <51> is required because DMI itself is not a primary preservative.

Oral solutions and suspensions in early-phase dose finding use DMI to form a concentrated stock solution before dilution into the dosing vehicle. The stock solution is prepared in a planetary mixer with vacuum deaeration; DMI is first combined with propylene glycol and poloxamer 188 at 40–50 °C, the active substance is dissolved, and the concentrate is diluted with purified water after cooling to 20–25 °C. The final DMI content is generally kept below 10% w/w of the oral liquid, producing a viscosity of 5–30 mPa·s at 20 °C that remains pourable and compatible with oral dosing syringes. DMI itself is not a primary preservative; if the oral liquid is multidose, a preservative such as methyl paraben or potassium sorbate is added and antimicrobial effectiveness is validated under USP <51>. Dose uniformity is demonstrated under USP <905> on the filled bottles or unit-dose cups. Container closure compatibility is screened with high-density polyethylene and amber polyethylene terephthalate bottles; DMI can migrate through low-density polyethylene liners, so the closure system is controlled by moisture loss not more than 0.1% per day at 25 °C and 60% RH. In suspension formulations, DMI is not used as a suspending agent; viscosity is supplied by xanthan gum or microcrystalline cellulose/carboxymethylcellulose sodium. The DMI amount per dose is calculated from the formulation density and the administered volume, then compared with the same ICH Q3C-derived limit used for tablet and capsule products.

In API crystallization, DMI serves as a high-temperature solvent for recrystallization when conventional alcohols or ketones do not dissolve the crude API at an acceptable concentration. Crude API is dissolved in DMI at 70–85 °C to a concentration of 150–250 mg/mL in a glass-lined reactor, and the solution is filtered through a 0.45 µm polytetrafluoroethylene depth filter to remove insoluble impurities. Crystallization is initiated by cooling from 75 °C to 5–10 °C at 10–20 °C/h and by adding purified water as antisolvent at 0.5–1.0 mL/min/kg of batch mass. The water-to-DMI ratio is ramped from 0:100 to 20:80 or 30:70 depending on the API solubility curve; excessive water addition rates produce fines and agglomerates. After a 2 h digestion at the final temperature, the crystals are isolated by filtration, washed with a chilled DMI-water mixture matching the final mother liquor composition, and dried under vacuum at 50–60 °C. Because DMI has a normal boiling point of 225 °C, residual solvent removal from the crystal surface is slower than for acetone or dichloromethane; a rotary vacuum dryer with a condensate trap is preferred over a tray dryer. Residual DMI in isolated crystals is controlled to ≤800 ppm before release for oral solid intermediates; for injectable-grade API the product is reslurried in water and dried to ≤100 ppm. Particle-size control is achieved by jet milling to a d90 of 10–20 µm for injectable microsuspensions or 30–50 µm for tablets. Crystal habit from DMI-water can be plate-like and poorly flowing; a seeded cooling profile at a seed loading of 0.5–2.0% w/w is used to promote equant crystals.